Canaccord Genuity adjusted their valuation of AxoGen, Inc. (NASDAQ: NASDAQ:AXGN), increasing the price target to $22.00 from the previous $18.00. The firm reaffirmed its Buy rating on the company's ...

Axogen Inc . (NASDAQ:AXGN), a leader in the regenerative medicine industry with a market capitalization of $833 million, has reached a new 52-week high, with its stock price climbing to $18.99.

The firm’s products include avance nerve graft, axoguard nerve connector, axoguard nerve protector, avive soft tissue membrane, acroval neurosensory and motor testing system, and axotouch two ...

Axogen’s product portfolio includes Avance® Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities ...

For more detailed information on nerve repair and grafting, the reader is referred to Orthopaedic Care: Medical and Surgical Management of Musculoskeletal Disorders (www.orthotextbook.net), which ...

The company’s products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated ...